
    
      This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute
      myeloid leukemia patients with 1st hematological CR. DSP-7888 is a novel cocktail peptide
      vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides. Primary
      endpoint is relapse-free survival, and 2nd endpoint is hematological relapse-free survival,
      overall survival and adverse event.
    
  